Mc. Stolzenberg et al., PURIFIED RECOMBINANT EBV DEOXYRIBONUCLEASE IN SEROLOGICAL DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA, International journal of cancer, 66(3), 1996, pp. 337-341
To evaluate applications of highly purified recombinant EBV DNAase in
the diagnosis and prognosis of NPC, we tested sera from patients with
NPC, other EBV-associated diseases and EBV-seropositive and -seronegat
ive healthy subjects by immunoblotting and DNAase inhibitory assay. Th
e results were compared with those obtained by the conventional immuno
fluorescence assays against the EBV-specified early antigens and capsi
d antigens. The antigenic specificity of the immunoblotting assay for
Ige antibody against the viral enzyme, but not that for the IgA antibo
dy, was correlated with DNAase-inhibitory activity of the sera and the
ir titers of IgG antibodies against the viral early antigens. Purified
IgA as well as IgG from NPC sera inhibited enzyme activity with simil
ar efficiency. The use of highly purified viral DNase has increased th
e sensitivity of detection of the corresponding antibodies by immunobl
otting, with the IgG antibody being detected in all but one, and IgA a
ntibody in all but 2, of the 174 NPC sera tested. The IgG antibody was
also commonly detected in the other groups of control sera, while the
IgA antibody was detected in about 10% of African Burkitt's lymphoma
and Algerian Hodgkin's lymphoma patients and less than 3% of the other
control subjects. These results suggest that IgA antibody against rec
ombinant EBV DNAase may be useful in the diagnosis of NPC, but the lev
el of this antibody did not appear to be related to clinical stages of
this cancer. (C) 1996 Wiley-Liss, Inc.